ArticleJournal of virus eradication2023
Antiviral activity of silver nanoparticles against the influenza A virus.
Article in Journal of virus eradication, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Integrating silver nanomaterials in wound healing: from physicochemical properties to clinical translation.Journal of nanobiotechnology · 2026Review
- The anticancer properties of the nanocomposite of low-nanoscale Ag nanoparticles obtained in SiOBMC pharmacology & toxicology · 2026Article
- Features and In Vitro Assessment of Antiviral Activity of Organic Coatings Doped with Silver-Based Compounds Against Human Coronavirus.International journal of molecular sciences · 2025Article
- Silver Nanoparticle-Mediated Antiviral Efficacy against Enveloped Viruses: A Comprehensive Review.Global challenges (Hoboken, NJ) · 2025Review
- Silver Nanoparticles (AgNPs) as Potential Antiviral Agents: Synthesis, Biophysical Properties, Safety, Challenges and Future Directions─Update Review.Molecules (Basel, Switzerland) · 2025Review
- Loading of Oregano Oil in Natural Nanogel and Preliminary Studies on Its Antiviral Activity on Betacoronavirus 1.Molecules (Basel, Switzerland) · 2025Article
- SnOACS applied bio materials · 2025Article
- Nasal Spray Disinfectant for Respiratory Infections Based on Functionalized Silver Nanoparticles: A Physicochemical and Docking Approach.Nanomaterials (Basel, Switzerland) · 2025Article
- Review
- Antiviral activity of silver nanoparticles against H1N1 influenza virus.BMC research notes · 2025Article
- Silver Nanoparticles: A Comprehensive Review of Synthesis Methods and Chemical and Physical Properties.Nanomaterials (Basel, Switzerland) · 2024Review
- Antiviral Activity of Graphene Oxide-Silver Nanocomposites Against Murine Betacoronavirus.International journal of nanomedicine · 2024Article
- Insight into Antiviral Activity of Ag/TiOInternational journal of nanomedicine · 2024Article
- "Therapeutic advancements in nanomedicine: The multifaceted roles of silver nanoparticles".Biotechnology notes (Amsterdam, Netherlands) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral infections occupy an essential place in modern medicine, particularly a large group of diseases caused by the influenza viruses. They are rapidly transmitted and mutate quickly, which can lead to significant socio-economic consequences. Silver nanoparticles (AgNPs) are considered to be an effective antimicrobial agent. This study shows that they have strong antiviral properties against the influenza A virus infection. Their absence of cytotoxicity at inhibitory concentrations demonstrates that they could be an effective antiviral agent against this virus. As AgNPs inhibit the influenza A virus replication and spread, they could also be successfully used as a post-infection virostatic agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.